For a complete list of publications see:

Lee EF, Smith NA, Soares da Costa TP, Meftahi N, Yao S, Harris TJ, Tran S, Pettikiriarachchi A, Perugini MA, Keizer DW, Evangelista M, Smith BJ and Fairlie WD (2019) Structural insights into bcl-2 pro-survival protein interactions with the key autophagy regulator Beclin 1 following phosphorylation by Mst1, Autophagy, 1-11.

Hockings C, Alsop AE, Fennell SC, Lee EF, Fairlie WD, Dewson G and Kluck RM (2018) Mcl-1 and Bcl-xL sequestration o 2 f Bak confers differential resistance to BH3-only proteins, Cell Death and Differ, 25(4): 719-732.

Brouwer JM, Lan P, Cowan AD, Bernardini JP, Birkinshaw RW, van Delft MF, Sleebs BE, Robin AY, Wardak A, Tan IK, Reljic B, Lee EF, Fairlie WD, Call MJ, Smith BJ, Dewson G, Lessene G, Colman PM and Czabotar PE (2017) Conversion of Bim-BH3 from Activator to Inhibitor of Bak through Structure-Based Design, Mol Cell., 68(4): 659-672.e9, doi: 10.1016/j.molcel.2017.11.001.

Chüeh AC, Tse JWT, Dickinson M, Ioannidis P, Jenkins L, Togel L, Tan B, Luk I, Davalos-Salas M, Nightingale R, Thompson MR, Williams BRG, Lessene G, Lee EF, Fairlie WD, Dhillon AS and Mariadason JM (2017) ATF3 Repression of BCL-XL Determines Apoptotic Sensitivity to HDAC Inhibitors across Tumor Types, Clin Cancer Res., 23(18): 5573-5584, doi: 10.1158/1078-0432.CCR-17-0466.

Young AI, Law AM, Castillo L, Chong S, Cullen HD, Koehler M, Herzog S, Brummer T, Lee EF, Fairlie WD, Lucas MC, Herrmann D, Allam A, Timpson P, Watkins DN, Millar EK, O'Toole SA, Gallego-Ortega D, Ormandy CJ, Oakes SR (2016) MCL-1 inhibition provides a new way to suppress breast cancer metastasis and increase sensitivity to dasatinib, Breast Cancer Res., 18(1): 125.

Rohrbeck L, Gong JN, Lee EF, Kueh AJ, Behren A, Tai L, Lessene G, Huang DC, Fairlie WD, Strasser A and Herold MJ (2016) Hepatocyte growth factor renders BRAF mutant human melanoma cell lines resistant to PLX4032 by downregulating the pro-apoptotic BH3-only proteins PUMA and BIM, Cell Death Differ, 23(12): 2054-62.

Berger S, Procko E, Margineantu D, Lee EF, Shen BW, Zelter A, Silva DA, Chawla K, Herold MJ, Garnier JM, Johnson R, MacCoss MJ, Lessene G, Davis TN, Stayton PS, Stoddard BL, Fairlie WD, Hockenbery DM and Baker D (2016) Computationally designed high specificity inhibitors delineate the roles of BCL2 family proteins in cancer, Elife, pii: e20352, doi: 10.7554/eLife.20352.

Young AI, Law AM, Castillo L, Chong S, Cullen HD, Koehler M, Herzog S, Brummer T, Lee EF, Fairlie WD, Lucas MC, Herrmann D, Allam A, Timpson P, Watkins DN, Millar EK, O’Toole SA, Gallego-Ortega D, Ormandy CJ and Oakes SR (2016) MCL-1 inhibition provides a new way to suppress breast cancer metastasis and increase sensitivity to dasatinib, Breast Cancer Res., 18(1): 125.

Yao S, Lee EF, Pettikiriachchi A, Evanglista M, Keizer DW and Fairlie WD (2016) Characterisation of the conformational preference and dynamics of the intrinsically disordered N-terminal region of Beclin 1 by NMR spectroscopy, Biochim Biophys Acta, 1864(9): 1128.

Lee EF, Grabow S, Chappaz S, Dewson G, Hockings C, Kluck RM, Debrincat MA, Gray DH, Witkowski MT, Evangelista M, Pettikiriarachchi A, Bouillet P, Lane RM, Czabotar PE, Colman PM, Smith BJ, Kile BT and Fairlie WD (2016) Physiological restraint of Bak by Bcl-xL is essential for cell survival, Genes Dev., 30(10): 1240-50.

Reljic B, Conos S, Lee EF, Garnier JM, Dong L, Lessene G, Fairlie WD, Vaux DL and Lindqvist LM (2016) BAX-BAK1-independent LC3B lipidation by BH3 mimetics is unrelated to BH3 mimetic activity and has only minimal effects on autophagic flux, Autophagy, 12(7): 1083-93.

Lee EF, Perugini MA, Pettikiriarachchi A, Evangelista M, Keizer D, Yao S and Fairlie WD (2015) The Beclin 1 N-terminal domain is intrinsically disordered, Autophagy, 12(3): 460-71.

Lee EF and Fairlie WD (2015) Repurposing apoptosis-inducing cancer drugs to treat schistosomiasis, Future Med Chem., 7(6): 707-11 (review).

Hockings C, Anwari K, Ninnis RL, Brouwer J, O'Hely M, Evangelista M, Hinds MG, Czabotar PE, Lee EF, Fairlie WD, Dewson G and Kluck RM (2015) Bid chimeras indicate that most BH3-only proteins can directly activate Bak and Bax, and show no preference for Bak versus Bax, Cell Death Dis., 6: e1735.

Lee EF, Takiguchi M, Pettikiriarachchi A, Evangelista M, Huang DCS, Dickins RA and Fairlie WD (2015) A transgenic mouse model to inducibly target pro-survival Bcl-2 proteins with selective BH3 peptides in vivo, Cell Death Dis., 6: e1679.

Carrington EM, Zhang J-G, Sutherland RM, Vikstrom IB, Brady JL, Soo P, Vremec D, Allison C, Lee EF, Fairlie WD, Bouillet P, Grabow S, Ottina E, Herold MJ, Pellegrini M, Huang DCS, Tarlinton DM, Strasser A, Lew AM and Zhan Y (2015) Profiling of Bcl-2 family members reveal a distinct apoptotic identity between conventional and plasmacytoid dendritic cells, Proc Natl Acad Sci USA, 112(13): 4044-49.

Peterson-Kaufman K, Haase H, Boersma M, Lee EF, Fairlie WD* and Gellman SH (2015) Residue-based preorganization of BH3-derived α/β-peptides: modulating affinity, selectivity and proteolytic susceptibility in α-helix mimics, ACS Chem Biol., 10: 1667-75.

Checco JW, Lee EF, Evangelista M, Sleebs NJ, Rogers K, Pettikiriarachchi A, Kershaw NJ,  Eddinger GA, Belair DG, Wilson JL, Eller CH, Raines RT, Murphy WL, Smith BJ, Gellman SH and Fairlie WD (2015) α/β peptide foldamers targeting intracellular protein-protein interactions with activity in living cells, J Am Chem Soc., 137(35): 11365-75.

Lee EF and Fairlie WD (2014) Apoptosis in schistosomes: toward novels treatments for schistosomiasis, Trends in Parisitol., 30(2): 75-84 (review).

Kelly GL, Grabow S, Glaser S, Fitzsimmons L, Aubrey BJ, Okamoto T,  Valente LJ,  Robati  M,  Tai L, Fairlie WD, Lee EF, Lindstrom MS,  Wiman KG, Huang DCS, Bouillet P, Rowe M, Rickinson AB, Herold MJ and Strasser A (2014) Targeting of MCL-1 kills MYC-driven mouse and human lymphomas even when they bear mutations in p53, Genes Dev., 25: 58-70.

Lee EF, Dewson G, Evangelista M, Pettikiriarachchi A, Gold GJ, Zhu H, Colman PM and Fairlie WD (2014) The functional differences between pro-survival and pro-apoptotic B cell lymphoma 2 (Bcl-2) proteins depend on structural differences in their Bcl-2 homology 3 (BH3) domains, J Biol Chem., 289(52): 36001-17.

Lang MJ, Brennan MS, O'Reilly LA, Ottina E, Czabotar PE, Whitlock E, Fairlie WD, Tai L, Strasser A and Herold MJ (2014) Characterisation of a novel A1-specific monoclonal antibody, Cell Death Dis., 5: e1553.

Czabotar PE, Westphal D, Dewson G, Ma S, Hockings C, Fairlie WD, Lee EF, Yao S, Robin AY, Smith BJ, Huang DC, Kluck RM, Adams JM and Colman PM (2013) Bax crystal structures reveal how BH3 domains activate Bax and nucleate its oligomerization to induce apoptosis, Cell, 152(3): 519-31.

Sleebs BE, Kersten WJ, Kulasegaram S, Nikolakopoulos G, Hatzis E, Moss RM, Parisot JP, Yang H, Czabotar PE, Fairlie WD, Lee EF, Adams JM, Chen L, van Delft MF, Lowes KN, Wei A, Huang DC, Colman PM, Street IP, Baell JB, Watson K and Lessene G (2013) Discovery of potent and selective benzothiazole hydrazone inhibitors of Bcl-XL, J Med Chem., 56(13): 5514-40.

Smith BJ, Lee EF, Checco JW, Evangelista M, Gellman SH and Fairlie WD (2013) Structure-guided rational design of α/β-peptide foldamers with high affinity for BCL-2 family prosurvival proteins, Chembiochem., 14(13): 1564-72.

*Co-corresponding author.